Drug Trial News

RSS

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).

7 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

KYTHERA ATX-101-10-16 trial for submental fat meets primary endpoints

KYTHERA Biopharmaceuticals, Inc. today announced the presentation of initial trial results from Study ATX-101-10-16, the first of two pivotal European Phase III clinical trials with ATX-101, a facial injectable drug for the reduction of unwanted fat under the chin, or submental fat.

7 May 2012

BioCryst first quarter revenues increase to $12.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2012.

7 May 2012

Clinical data from Anacor’s tavaborole and AN2728 study to be presented at upcoming meetings

Anacor Pharmaceuticals announced today that it will be presenting clinical data on its lead compounds, tavaborole and AN2728, at the following upcoming medical meetings.

5 May 2012

Ocular Therapeutix initiates travoprost-loaded punctum plug trial in glaucoma

Ocular Therapeutix, Inc. announced today the commencement of a sustained release travoprost-loaded punctum plug feasibility study for the treatment of glaucoma.

5 May 2012

Teva announces new data from women's health franchise

Teva Women's Health today announced new data from the Company's expanding women's health franchise will be featured at the 60th Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) in San Diego, California, May 5-9, 2012.

5 May 2012

Flavan-3-ols, SoyLife can improve biomarkers of CVD risk in postmenopausal type 2 diabetic patients

A new, one-year, double-blind controlled clinical study shows that cacao-flavonoids and soy isoflavones can significantly improve biomarkers of CVD risk in postmenopausal women with type 2 diabetes.

5 May 2012

Pfizer terminates Lyrica Phase 3 trial on neuropathic pain associated with HIV neuropathy

Pfizer Inc. announced today that it has stopped a Phase 3 clinical trial of Lyrica (pregabalin) in patients with neuropathic pain associated with HIV neuropathy, a form of nerve damage characterized by burning pain usually beginning in the feet. The decision follows review of a planned interim analysis of the study by the trial's external Data Monitoring Committee.

5 May 2012

Isis commences ISIS-APOCIIIRx Phase 2 study in hypertriglyceridemia

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study evaluating ISIS-APOCIIIRx in patients with hypertriglyceridemia.

5 May 2012

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

Pfizer Inc. announced today that a Phase 3 randomized withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy (pDPN) did not meet its primary efficacy endpoint, change in endpoint mean pain score relative to baseline.

5 May 2012

New analysis may help identify breast cancer patients who will benefit from immune suppressant

A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, say French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium.

4 May 2012

CSL Behring commences C1-INH phase I/II study in hereditary angioedema

CSL Behring announced today that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with hereditary angioedema.

4 May 2012

Generon commences F-627 Phase II trial in breast cancer

Generon Corporation Ltd. today announced the initiation of a Phase II clinical trial for F-627 after US FDA regulatory clearance. The current study is a Phase II, randomized, multicenter, open-label, active-controlled trial of F-627 in women with breast cancer receiving myelotoxic chemotherapy.

4 May 2012

Abbott to purchase AP214 hormone analogue from Action Pharma

Abbott and Action Pharma A/S, a privately owned company, today announced that they have entered into an agreement in which Abbott will acquire AP214 from Action Pharma.

4 May 2012

Clinical trial to investigate statins in patients with acute severe respiratory failure

Queen's University and NUI Galway and are leading a clinical trial to investigate the possibility that statins, a drug commonly used to combat cholesterol, might help patients with acute severe respiratory failure.

4 May 2012

Varenicline reduces alcohol intake among heavy-drinking smokers

The smoking cessation drug varenicline significantly reduced alcohol consumption in a group of heavy-drinking smokers, in a study carried out by researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco.

4 May 2012

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes.

4 May 2012

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's Respiratory Syncytial Virus (RSV) vaccine program.

4 May 2012

NCIC CTG, Oncolytics to conduct REOLYSIN Phase II study in colorectal cancer

Oncolytics Biotech Inc. announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer.

4 May 2012

Drug Trial News

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

KYTHERA ATX-101-10-16 trial for submental fat meets primary endpoints

BioCryst first quarter revenues increase to $12.2 million

Clinical data from Anacor’s tavaborole and AN2728 study to be presented at upcoming meetings

Ocular Therapeutix initiates travoprost-loaded punctum plug trial in glaucoma

Teva announces new data from women's health franchise

Flavan-3-ols, SoyLife can improve biomarkers of CVD risk in postmenopausal type 2 diabetic patients

Pfizer terminates Lyrica Phase 3 trial on neuropathic pain associated with HIV neuropathy

Isis commences ISIS-APOCIIIRx Phase 2 study in hypertriglyceridemia

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

New analysis may help identify breast cancer patients who will benefit from immune suppressant

CSL Behring commences C1-INH phase I/II study in hereditary angioedema

Generon commences F-627 Phase II trial in breast cancer

Abbott to purchase AP214 hormone analogue from Action Pharma

Clinical trial to investigate statins in patients with acute severe respiratory failure

Varenicline reduces alcohol intake among heavy-drinking smokers

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

NCIC CTG, Oncolytics to conduct REOLYSIN Phase II study in colorectal cancer

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News